Gene · 3694
ITGB6: integrin subunit beta 6
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ITGB6: integrin subunit beta 6. Genes, record 3694. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3694
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P18564 | Integrin beta-6 | 788 | 14 | Ensembl, GeneID, HGNC |
Source UniProt
Patents119
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 49988 | P18564 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 49989 | P18564 | Espacenet |
| WO 2025253854 A | 2025-12-11 | 2 | P18564 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 3198 | P18564 | Espacenet |
| WO 2025228986 A1 | 2025-11-06 | 6 | P18564 | Espacenet |
| EP 4644537 A1 | 2025-11-05 | 6 | P18564 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 2764 | P18564 | Espacenet |
| EP 4633740 A2 | 2025-10-22 | 857 | P18564 | Espacenet |
| EP 4631545 A1 | 2025-10-15 | 2 | P18564 | Espacenet |
| WO 2025199077 A1 | 2025-09-25 | 185 | P18564 | Espacenet |
1 to 10 of 119
See all 119 patentsDrugs4
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ABITUZUMAB | CHEMBL2109621 | Integrin alpha-V/beta-6 inhibitor | INHIBITOR | ChEMBL |
| SIGVOTATUG | CHEMBL5314878 | Integrin beta-6 inhibitor | INHIBITOR | ChEMBL |
| SIGVOTATUG VEDOTIN | CHEMBL5314879 | Integrin beta-6 binding agent | BINDING AGENT | ChEMBL |
| STX-100 | CHEMBL2109623 | Integrin alpha-V/beta-6 inhibitor | INHIBITOR | ChEMBL |
Trials11
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07227298 | SIGVOTATUG VEDOTIN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT06758401 | SIGVOTATUG VEDOTIN | PHASE3 | ClinicalTrials.gov | |
| NCT06012435 | SIGVOTATUG VEDOTIN | PHASE3 | ClinicalTrials.gov | |
| NCT03688230 | ABITUZUMAB | PHASE2 | ClinicalTrials.gov | |
| NCT03573505 | STX-100 | PHASE2 | 2020-11-20 | ClinicalTrials.gov |
| NCT02745145 | ABITUZUMAB | PHASE2 | 2019-06-18 | ClinicalTrials.gov |
| NCT01371305 | STX-100 | PHASE2 | 2020-02-28 | ClinicalTrials.gov |
| NCT01360840 | ABITUZUMAB | PHASE2 | 2015-12-14 | ClinicalTrials.gov |
| NCT01008475 | ABITUZUMAB | PHASE1/PHASE2 | 2016-03-30 | ClinicalTrials.gov |
| NCT00958477 | ABITUZUMAB | PHASE1 | 2017-08-02 | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsNIH grants1,044
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ITGB6 papers | Newest fiscal year |
|---|---|---|---|
| P30CA068485 | Cancer Center Support Grant | 5 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 4 | 2025 |
| P30CA093373 | Cancer Center Support Grant P30 | 4 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 4 | 2025 |
| P30CA010815 | Consolidated Basic Cancer Research Program | 3 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 3 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 3 | 2025 |
| P30CA077598 | Cancer Center Support Grant | 3 | 2025 |
| R01DK062370 | Identifying Genes for Type 2 Diabetes: FUSION | 3 | 2025 |
| R01HL127349 | Genomic Analysis of Tissue and Cellular Heterogeneity in IPF | 3 | 2025 |
1 to 10 of 1,044Source NIH's project files
See all 1,044 nih grantsPapers1,301
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Role of Integrin Family in Atherosclerotic Cardiovascular Disease: A Prospective Cohort Study and Mendelian Randomization Analysis. | Biomedicines | 2026 | 42652217 | PubTator, text mining | PubMed |
| Integrin β6-Targeted CAR-T Cells exhibit potent antitumor activity in β6-Positive pancreatic ductal adenocarcinoma and lung adenocarcinoma. | Mol Cancer Ther | 2026 | 42594406 | PubTator, text mining | PubMed |
| Tetrandrine-loaded phenylboronic acid-chitosan nanoparticles for enhanced corneal penetration and anti-fibrotic therapy. | Int J Pharm | 2026 | 42567377 | PubTator, text mining | PubMed |
| PF-08046876, a differentiated integrin beta-6 antibody-drug conjugate delivering a potent camptothecin payload optimized for bystander effect and reduced drug efflux. | Mol Cancer Ther | 2026 | 42515977 | PubTator, text mining | PubMed |
| Stanniocalcin 1 promotes gastric cancer progression by activating the PI3K/AKT pathway and inducing M2 macrophage polarization via the JAK2/STAT3/lL-10 axis. | Chin Med J (Engl) | 2026 | 42484012 | PubTator, text mining | PubMed |
| Advances in antibody-drug conjugate-based combination therapy strategies for non-small cell lung cancer. | Expert Opin Biol Ther | 2026 | 42467409 | PubTator, text mining | PubMed |
| Long-term ocular symptoms following COVID-19 linked to immune dysregulation, dysautonomia and peripheral neuropathy. | Nat Commun | 2026 | 42420292 | PubTator, text mining | PubMed |
| Distinct motility and pro-fibrotic effect of renal tubule-derived extracellular vesicles in fibrotic extracellular matrix. | Acta Biomater | 2026 | 42413712 | PubTator, text mining | PubMed |
| LLPS-based classification and a novel prognostic signature reveal NRF1 as a therapeutic target in pancreatic cancer. | Cancer Cell Int | 2026 | 42363116 | PubTator, text mining | PubMed |
| Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC). | ESMO Open | 2026 | 42330841 | PubTator, text mining | PubMed |
1 to 10 of 1,301
See all 1,301 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3694
GET https://conductscience.org/api/genes/v1/3694/patents?page=2